Skip to main content
Caplight Logo









Quoin Pharmaceuticals

Quoin Pharmaceuticals

Public
Ashburn, VirginiaHealthcarehttps://quoinpharma.com/

Quoin Pharmaceuticals is now publicly traded

The data on this page reflects Quoin Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Sep 10, 2026

Total Funding Raised

$50M

Company Overview

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops and commercializes therapeutic products for rare and orphan diseases.

Sector

Healthcare

AI Layer

Non-AI

Keywords

rare disease therapeuticsorphan drugdermatological treatmentstopical drugrare pediatric diseaseclinical-stage biotechbiotech startupskin barrier therapydrug developmentFDA designationspecialty pharmaNetherton SyndromeEpidermolysis BullosaPeeling Skin SyndromePalmoplantar Keratoderma

Quoin Pharmaceuticals Comparables

Compare Quoin Pharmaceuticals with similar companies based on industry and business-model similarity.

No public comparables are available for Quoin Pharmaceuticals. Request access to learn about comparables coverage.

Request access

Quoin Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 10, 2026

Key People

Founding team and executive leadership

Michael Myers

Co-Founder Quoin Pharmaceuticals, Inc. and CEO

Founding Team

Sally Lawlor

Chief Financial Officer

Executive Team

Quoin Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Quoin Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersAshburn, Virginia
Employee Range9
Year Founded2018
Last FundingSep 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?